Author Correction: Tau-targeting antisense oligonucleotide MAPT_Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

Affiliations

• ¹ Dementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London, London, UK. c.mummery@ucl.ac.uk.
• ² Karolinska University Hospital, ME Aging, Stockholm, Sweden.
• ³ Sheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK.
• ⁴ Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
• ⁵ University Medical Center Groningen / RUG, Alzheimer Center Groningen, Groningen, the Netherlands.
• ⁶ Douglas Mental Health University Institute and McConnell Brain Imaging Centre of the Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
• ⁷ Memory Clinic, Psychiatry - Cognition and Geriatric Psychiatry, Sahlgrenska University Hospital, Gothenburg/Molndal, Sweden.
• ⁸ German Center for Neurodegenerative Diseases, DZNE, and Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
• ⁹ CRST Oy; Turku PET Centre University of Turku and Turku University Hospital, Turku, Finland.
• ¹⁰ Department of Neurology University of Ulm and DZNE, Ulm, Germany.
• ¹¹ Pharmakologisches Studienzentrum Chemnitz GmbH Mittweida, Mittweida, Germany.
• ¹² Ionis Pharmaceuticals, Carlsbad, CA, USA.
• ¹³ Biogen, Cambridge, MA, USA.